ALS Clinical Trial
Official title:
T Cell Phenotypes in ALS, Influence of Vitamin D
ALS is a devastative disorder characterized by motor neuron degeneration. Median survival is 3 years after onset, but may vary from a few months to more than 30 years. Various factors have been suspected to play a role in such a variation, but recently, it has been described that regulatory T-lymphocytes (T regs) may mediate ALS progression and survival. Vitamin D is an hormone know to regulated T reg function in vivo and in vitro. It have recently demonstrated that vitamin D (VD) levels correlated with ALS prognosis. The investigator want to go further in the study of the immune processes that could modulate prognosis in ALS. This could allow proposing VD as a potential treatment of ALS in a future trial. More largely, this could reinforce arguments in favor of an immune intervention to attenuate the severity of this devastating disorder.
ALS is a devastative disorder characterized by motor neuron degeneration. Median survival is 3 years after onset, but may vary from a few months to more than 30 years. Various factors have been suspected to play a role in such a variation, but recently, it has been described that regulatory T-lymphocytes (T regs) may mediate ALS progression and survival. Vitamin D is an hormone know to regulated T reg function in vivo and in vitro. It have recently demonstrated that vitamin D (VD) levels correlated with ALS prognosis and patients with a severe VD deficiency had a 6 time more rapid evolution than those with normal VD levels. The investigator want to go further in the study of the immune processes that could modulate prognosis in ALS. We propose 1- to study T cell phenotypes (Treg, CD4 (cluster of differentiation 4) -Th1, -Th17, -Th2, CD8 (cluster of differentiation 8)and NK) in ALS vs controls ; 2- In VD-deficient patients, to analyze the influence of a vitamin D supplementation on T cell phenotypes ; 3- to study the relationships between T cell phenotypes and ALS prognostic factors. The project will include 70 ALS patients and 27 controls in this prospective study. VD-deficient patients will be supplemented, according to national recommendations for 6 months, and the evolution of T cell phenotypes will be followed over 1 year. We hope to demonstrate first that T cell phenotypes in ALS are consistent with a pro inflammatory profile, compared to controls, secondly that VD treatment modulates T cell phenotypes towards a non-inflammatory one and, thirdly, that inflammatory T cell phenotypes correlate with a worse prognosis of the disease. This could allow proposing VD as a potential treatment of ALS in a future trial. More largely, this could reinforce arguments in favor of an immune intervention to attenuate the severity of this devastating disorder. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04948645 -
A Phase 1 Study to Investigate the Safety and Pharmacokinetics of ABBV-CLS-7262 in Patients With Amyotrophic Lateral Sclerosis
|
Phase 1 | |
Completed |
NCT02405182 -
MRI Biomarkers in ALS
|
||
Completed |
NCT00696332 -
Talampanel for Amyotrophic Lateral Sclerosis (ALS)
|
Phase 2 | |
Recruiting |
NCT03865420 -
Amyotrophic Lateral Sclerosis (ALS) Families Project
|
||
Terminated |
NCT04054141 -
rTMS in Treatment of Spasticity
|
N/A | |
Recruiting |
NCT03272503 -
A Clinical Trial of Pimozide in Patients With Amyotrophic Lateral Sclerosis (ALS)
|
Phase 2 | |
Completed |
NCT05568615 -
Extension Study Following the Studies MT-1186-A03 or A04 to Evaluate the Safety of Oral Edaravone in Subjects With ALS
|
Phase 3 | |
Recruiting |
NCT05635266 -
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
|
||
Active, not recruiting |
NCT04259255 -
Radicava® (Edaravone) Findings in Biomarkers From ALS (REFINE-ALS)
|
||
Recruiting |
NCT02495571 -
Assessment of Voluntary and Reflex Cough in Patients With ALS
|
N/A | |
Completed |
NCT02525471 -
A Pilot Study of RNS60 in Amyotrophic Lateral Sclerosis (ALS)
|
Phase 1 | |
Recruiting |
NCT05031351 -
NF-κB Inhibition in Amyotrophic Lateral Sclerosis
|
Phase 2 | |
Active, not recruiting |
NCT05581771 -
Factors Associated With Success of NIPPV in ALS Patients
|
||
Active, not recruiting |
NCT03268603 -
Intrathecal Autologous Adipose-derived Mesenchymal Stromal Cells for Amyotrophic Lateral Sclerosis (ALS)
|
Phase 2 | |
Recruiting |
NCT05271435 -
Digital Tools for Assessment of Motor Functions and Falls in ALS
|
||
Completed |
NCT06005506 -
National Multicenter Interventional Study Aimed at Evaluating the Effect on the Intestinal Microbiota in Chronically Frail Patients Who Share Alterations in Intestinal Function.
|
N/A | |
Recruiting |
NCT04138095 -
Virtual Reality as an Adjunct to Management of Pain and Anxiety in Palliative Care
|
N/A | |
Recruiting |
NCT03698149 -
ECoG BMI for Motor and Speech Control
|
N/A | |
Not yet recruiting |
NCT05621213 -
Satisfaction of Patients With Amyotrophic Lateral Sclerosis Regarding Home Assisted Teleconsultation
|
N/A | |
Terminated |
NCT03373981 -
Non-invasive Brain Stimulation for the Treatment of Depression Symptoms in ALS
|
N/A |